title: Vaccination with the ospA- and ospB-Negative Borrelia burgdorferi Strain 50772 Provides Significant Protection against Canine Lyme Disease.
abstract: Beagles received placebo or ospA- and ospB-negative Borrelia burgdorferi before a tick challenge. A total of 28 (41%) ticks and skin biopsy specimens from each control dog (n = 10) contained B. burgdorferi. In contrast, 12 (19%) ticks recovered from the vaccine recipients (n = 10) were infected (P = 0.0077), and 5 dogs yielded spirochetes from the skin biopsy specimens (P = 0.0325). In addition, 9 (90%) placebo recipients and 4 (40%) vaccine recipients developed joint abnormalities (P = 0.0573). Therefore, vaccination with the ospA- and ospB-negative spirochete provided significant protection against Lyme disease.
authors.affiliation: Merck Animal Health, Inc., Elkhorn, Nebraska, USA.
authors.forename: Rhonda L
authors.initials: RL
authors.lastname: LaFleur
authors.affiliation: Gundersen Health System, La Crosse, Wisconsin, USA smcallis@gundersenhealth.org.
authors.forename: Steven M
authors.initials: SM
authors.lastname: Callister
authors.affiliation: Merck Animal Health, Inc., Elkhorn, Nebraska, USA.
authors.forename: Jennifer C
authors.initials: JC
authors.lastname: Dant
authors.affiliation: Merck Animal Health, Inc., Elkhorn, Nebraska, USA.
authors.forename: Terri L
authors.initials: TL
authors.lastname: Wasmoen
authors.affiliation: Gundersen Health System, La Crosse, Wisconsin, USA.
authors.forename: Dean A
authors.initials: DA
authors.lastname: Jobe
authors.affiliation: Gundersen Health System, La Crosse, Wisconsin, USA.
authors.forename: Steven D
authors.initials: SD
authors.lastname: Lovrich
mesh_terms: D000818:Animals; D000942:Antigens, Bacterial / Q000235:genetics; D000954:Antigens, Surface; D001425:Bacterial Outer Membrane Proteins / Q000235:genetics; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D025065:Borrelia burgdorferi / Q000235:genetics / Q000276:immunology*; D004283:Dog Diseases / Q000276:immunology* / Q000517:prevention & control*; D004285:Dogs; D008074:Lipoproteins / Q000172:deficiency; D008193:Lyme Disease / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary*; D010919:Placebos; D016896:Treatment Outcome; D014611:Vaccination / Q000379:methods*; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology
chemical_list: D000942:Antigens, Bacterial; D000954:Antigens, Surface; D001425:Bacterial Outer Membrane Proteins; D001428:Bacterial Vaccines; D008074:Lipoproteins; C072045:OspA protein; D010919:Placebos; D014613:Vaccines, Attenuated; C077030:OspB protein, Borrelia burgdorferi